AstraZeneca: Oddo BHF still a seller
(CercleFinance.com) - On Wednesday morning an Oddo BHF analyst confirmed a "Reduce" rating on the AstraZeneca share, after a pause in phase 3 of the Covid-19 vaccine following a serious side effect.
According to the NY Times this is a case in the UK of rare inflammation of the spinal cord (transverse myelitis). This type of inflammation can occur following a viral infection - however, remember that the AZN vaccine is based on a viral vector (Adenovirus of himpanzee). AstraZeneca says that it is putting this on hold in order to shed light on the origin of this serious case, the broker says.
Oddo BHF thus confirms its target price of 7.600 pence for the share (8% downside).
Copyright (c) 2020 CercleFinance.com. All rights reserved.
According to the NY Times this is a case in the UK of rare inflammation of the spinal cord (transverse myelitis). This type of inflammation can occur following a viral infection - however, remember that the AZN vaccine is based on a viral vector (Adenovirus of himpanzee). AstraZeneca says that it is putting this on hold in order to shed light on the origin of this serious case, the broker says.
Oddo BHF thus confirms its target price of 7.600 pence for the share (8% downside).
Copyright (c) 2020 CercleFinance.com. All rights reserved.